COLGATE PALMOLIVE CO Form 10-Q November 07, 2003

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2003.
OR
[] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

COLGATE-PALMOLIVE COMPANY

Commission File Number 1-644

 $(Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter)$

Delaware (State or other jurisdiction of incorporation or organization)

Common, \$1.00 par value

13-1815595 (I.R.S. Employer Identification No.)

300 Park Avenue, New York, New York	10022
(Address of principal executive offices)	(Zip Code)

(212) 310-2000

(Registrant s telephone number, including area code)

NO CHANGES

(Former name, former address, and former fiscal year, if changed since last report)

of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes X No Indicate the number of shares outstanding of each of the issuer s classes of common stock, as of the latest practicable date: Class Shares Outstanding Date
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes X No
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act

537,239,676

September 30, 2003

PART I. FINANCIAL INFORMATION

COLGATE-PALMOLIVE COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Dollars in Millions Except Per Share Amounts)

(Unaudited)

		Three Months Ended September 30,			Nine Months Ended September 30,		
	2003		2002	200	03		2002
Net sales	\$ 2,523	3.8 \$	2,381.7	\$ 7,3	30.8	\$ 6	,873.9
Cost of sales	1,130		1,079.1		92.5		,124.5
Gross profit	1,38	7.3	1,302.6	4,0	38.3	3	,749.4
Selling, general and administrative expenses	852		788.5		35.0		,256.8
Operating profit	539	5.3	514.1	1,6	03.3	1	,492.6
Interest expense, net	30).4	38.7		95.7		110.7
Income before income taxes	504	10	475.4	1.5	07.6	1	,381.9
Provision for income taxes	139		144.7		58.4	1	434.5
Net income	\$ 369	5.4 \$	330.7	\$ 1,0	49.2	\$	947.4
Earnings per common share, basic	\$.	67 \$.60	\$	1.92	\$	1.71
Earnings per common share, diluted	\$.	63 \$.57	\$	1.81	\$	1.60
Dividends declared per common share		24 \$.18	\$.66	\$.54
Dividends deciated per common share	φ .	∠- • ⊅	.10	Φ	.00	Φ	.54

See Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in Millions Except Per Share Amounts)

(Unaudited)

	September 30, 2003	December 31, 2002	
Assets			
Current Assets			
Cash and cash equivalents	\$ 256.1	\$ 167.9	
Receivables (net of allowances of \$51.2 and \$45.9, respectively)	1,195.4	1,145.4	
Inventories	772.8	671.7	
Other current assets	250.6	243.1	
Total current assets	2,474.9	2,228.1	
Property, plant and equipment:			
Cost	4,918.5	4,656.9	
Less: Accumulated depreciation	2,416.1	2,165.6	
	2,502.4	2,491.3	
Goodwill, net	1,280.4	1,182.8	
Other intangible assets, net	600.2	608.5	
Other assets	548.1	576.5	
Total assets	\$ 7,406.0	\$ 7,087.2	
Liabilities and Shareholders Equity			
Current Liabilities			
Notes and loans payable	\$ 100.0	\$ 94.6	
Current portion of long-term debt	403.8	298.5	
Accounts payable	687.8	728.3	
Accrued income taxes	169.3	121.7	
Other accruals	1,058.4	905.6	
Total current liabilities	2,419.3	2,148.7	
Long-term debt	2,731.9	3,210.8	
Deferred income taxes	542.3	488.8	
Other liabilities	875.3	888.6	
Shareholders Equity			
Preferred stock	307.8	323.0	

Common stock	732.9	732.9
Additional paid-in capital	1,071.6	1,133.9
Retained earnings	7,201.3	6,518.5
Accumulated other comprehensive income	(1,828.5)	(1,865.6)
	7,485.1	6,842.7
Unearned compensation	(333.0)	(340.1)
Treasury stock, at cost	(6,314.9)	(6,152.3)
Total shareholders equity	837.2	350.3
Total liabilities and shareholders equity	\$ 7,406.0	\$ 7,087.2

See Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in Millions Except Per Share Amounts)

(Unaudited)

Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0		Nine Mont Septeml	
Net income \$ 1,049.2 \$ 947.4 Adjustments to reconcile net income to net cash provided by operations: 230.6 218.7 Depreciation and amortization (63.1) (50.0) Deferred income taxes 17.4 29.1 Cash effects of changes in: Teceivables (10.4) (17.8) Receivables (74.3) (34.4) Accounts payable and other accruals 75.6 105.2 Other non-current assets and liabilities 54.7 5.3 Net cash provided by operations 1,279.7 1,203.5 Investing Activities: (187.1) (214.0) Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: (537.1) (624.2) Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) 305.8		2003	2002
Adjustments to reconcile net income to net cash provided by operations: 230.6 218.7 Depreciation and amortization (63.1) (50.0) Voluntary contributions to benefit plans (63.1) (50.0) Deferred income taxes 17.4 29.1 Cash effects of changes in: **** **** Receivables (10.4) (17.8) Receivables (74.3) (34.4) Accounts payable and other accruals 75.6 105.2 Other non-current assets and liabilities 54.7 5.3 Net cash provided by operations 1,279.7 1,203.5 Investing Activities: Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: *** *** Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt (23.6) (366.4) 305.8	Operating Activities:		
Depreciation and amortization 230.6 218.7 Voluntary contributions to benefit plans (63.1) (50.0) Deferred income taxes 17.4 29.1 Cash effects of changes in:	Net income	\$ 1,049.2	\$ 947.4
Voluntary contributions to benefit plans (63.1) (50.0) Deferred income taxes 17.4 29.1 Cash effects of changes in: Receivables (10.4) (17.8) Inventories (74.3) (34.4) Accounts payable and other accruals 75.6 105.2 Other non-current assets and liabilities 54.7 5.3 Net cash provided by operations 1,279.7 1,203.5 Investing Activities: Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: Proceeds from issuance of debt 123.1 857.8 Prividends paid (36.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange ra			
Deferred income taxes 17.4 29.1 Cash effects of changes in: (10.4) (17.8) Receivables (74.3) (34.4) Accounts payable and other accruals 75.6 105.2 Other non-current assets and liabilities 54.7 5.3 Net cash provided by operations 1,279.7 1,203.5 Investing Activities: 2 (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: 2 (537.1) (624.2) Proceeds from issuance of debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash			218.7
Cash effects of changes in: (10.4) (17.8) Receivables (10.4) (17.4) (34.4) Accounts payable and other accruals 75.6 105.2 Other non-current assets and liabilities 54.7 5.3 Net cash provided by operations 1,279.7 1,203.5 Investing Activities: (187.1) (214.0) Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: (136.6) (227.0) Financing Activities: (136.6) (227.0) Proceeds from issuance of debt (537.1) (624.2) Proceeds from issuance of debt (136.6) (305.8) Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6)		. ,	
Receivables (10.4) (17.8) Inventories (74.3) (34.4) Accounts payable and other accruals 75.6 105.2 Other non-current assets and liabilities 54.7 5.3 Net cash provided by operations 1,279.7 1,203.5 Investing Activities: Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: Frincipal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2		17.4	29.1
Inventories (74.3) (34.4) Accounts payable and other accruals 75.6 105.2 Other non-current assets and liabilities 54.7 5.3 Net cash provided by operations 1,279.7 1,203.5 Investing Activities: (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: 27.0 (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0			
Accounts payable and other accruals 75.6 105.2 Other non-current assets and liabilities 54.7 5.3 Net cash provided by operations 1,279.7 1,203.5 Investing Activities: 2 (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: 2 Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0			
Other non-current assets and liabilities 54.7 5.3 Net cash provided by operations 1,279.7 1,203.5 Investing Activities: 2 2 Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: 2 Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt (537.1) (624.2) 857.8 Dividends paid (366.4) (305.8) 92.5 Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0		* *	
Net cash provided by operations 1,279.7 1,203.5 Investing Activities: (187.1) (214.0) Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: (537.1) (624.2) Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0			
Investing Activities: Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: *** Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0	Other non-current assets and liabilities	54.7	5.3
Investing Activities: Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: *** Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0			
Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0	Net cash provided by operations	1,279.7	1,203.5
Capital expenditures (187.1) (214.0) Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0			
Sales (purchases) of marketable securities and investments 51.3 (13.5) Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0			
Other (0.8) 0.5 Net cash used in investing activities (136.6) (227.0) Financing Activities: *** Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0			(214.0)
Financing Activities: (537.1) (624.2) Principal payments on debt (537.1) (624.2) Proceeds from issuance of debt 123.1 857.8 Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0	Sales (purchases) of marketable securities and investments	51.3	(13.5)
Financing Activities: Principal payments on debt Proceeds from issuance of debt Dividends paid Purchases of common and preferred shares Proceeds from exercise of stock options Total Cash used in financing activities Effect of exchange rate changes on cash and cash equivalents Financing Activities: (537.1) (624.2) 857.8 (366.4) (305.8) (348.7) (929.5) 71.5 52.7 (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 88.2 28.0	Other	(0.8)	0.5
Financing Activities: Principal payments on debt Proceeds from issuance of debt Dividends paid Purchases of common and preferred shares Proceeds from exercise of stock options Total Cash used in financing activities Effect of exchange rate changes on cash and cash equivalents Financing Activities: (537.1) (624.2) 857.8 (366.4) (305.8) (348.7) (929.5) 71.5 52.7 (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 88.2 28.0			
Principal payments on debt(537.1)(624.2)Proceeds from issuance of debt123.1857.8Dividends paid(366.4)(305.8)Purchases of common and preferred shares(348.7)(929.5)Proceeds from exercise of stock options71.552.7Net cash used in financing activities(1,057.6)(949.0)Effect of exchange rate changes on cash and cash equivalents2.70.5Net increase in cash and cash equivalents88.228.0	Net cash used in investing activities	(136.6)	(227.0)
Principal payments on debt(537.1)(624.2)Proceeds from issuance of debt123.1857.8Dividends paid(366.4)(305.8)Purchases of common and preferred shares(348.7)(929.5)Proceeds from exercise of stock options71.552.7Net cash used in financing activities(1,057.6)(949.0)Effect of exchange rate changes on cash and cash equivalents2.70.5Net increase in cash and cash equivalents88.228.0			
Principal payments on debt(537.1)(624.2)Proceeds from issuance of debt123.1857.8Dividends paid(366.4)(305.8)Purchases of common and preferred shares(348.7)(929.5)Proceeds from exercise of stock options71.552.7Net cash used in financing activities(1,057.6)(949.0)Effect of exchange rate changes on cash and cash equivalents2.70.5Net increase in cash and cash equivalents88.228.0	Financing Activities:		
Dividends paid (366.4) (305.8) Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0		(537.1)	(624.2)
Purchases of common and preferred shares (348.7) (929.5) Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0	Proceeds from issuance of debt	123.1	857.8
Proceeds from exercise of stock options 71.5 52.7 Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0	Dividends paid	(366.4)	(305.8)
Net cash used in financing activities (1,057.6) (949.0) Effect of exchange rate changes on cash and cash equivalents 2.7 0.5 Net increase in cash and cash equivalents 88.2 28.0	Purchases of common and preferred shares	(348.7)	(929.5)
Effect of exchange rate changes on cash and cash equivalents 2.7 O.5 Net increase in cash and cash equivalents 88.2 28.0	Proceeds from exercise of stock options	71.5	52.7
Effect of exchange rate changes on cash and cash equivalents 2.7 O.5 Net increase in cash and cash equivalents 88.2 28.0			
Net increase in cash and cash equivalents 88.2 28.0	Net cash used in financing activities	(1,057.6)	(949.0)
	Effect of exchange rate changes on cash and cash equivalents	2.7	0.5
	Net increase in cash and cash equivalents	88.2	28.0
	Cash and cash equivalents at beginning of period	167.9	172.7

Cash and cash equivalents at end of period	\$ 256.1	\$ 200.7
Supplemental Cash Flow Information:		
Income taxes paid	\$ 333.6	\$ 449.0

See Notes to Condensed Consolidated Financial Statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in Millions Except Per Share Amounts)

(Unaudited)

1. The Condensed Consolidated Financial Statements reflect all normal recurring adjustments which, in management s opinion, are necessary for a fair presentation of the results for interim periods. Results of operations for the interim periods may not be representative of results to be expected for a full year.

Reference is made to the Company s Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2002, for a complete set of financial notes including the Company s significant accounting policies.

- Provision for certain expenses, including income taxes, media advertising and consumer promotion are based on full year assumptions and
 are included in the accompanying Condensed Consolidated Financial Statements in proportion with estimated annual tax rates, the passage
 of time or estimated annual sales.
- 3. Inventories by major classes were as follows:

	September 2003	30, December 31, 2002
Raw materials and supplies	\$ 190).9 \$ 176.6
Work-in-process	37	7.6 30.1
Finished goods	544	
	\$ 772	2.8 \$ 671.7

Comprehensive Income

Comprehensive income is comprised of net income, currency translation gains and losses, and gains and losses from derivative instruments designated as cash flow hedges. Total comprehensive income for the three months ended September 30, 2003 and 2002 was \$349.8 and \$201.8, respectively. Total comprehensive income for the nine months ended September 30, 2003 and 2002 was \$1,086.3 and \$626.3, respectively. The difference from net income primarily consists of foreign currency translation adjustments. Accumulated other comprehensive income, as reflected in the Condensed Consolidated Balance Sheets, primarily consists of cumulative foreign currency translation adjustments.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in Millions Except Per Share Amounts)

(Unaudited)

5. Earnings Per Share

Thron	Months	Ended

	Septen	September 30, 2003			September 30, 2002		
			Per			Per	
	Income	Shares	Share	Income	Shares	Share	
Net income	\$ 365.4			\$ 330.7			
Preferred dividends	(6.8)			(5.5)			
Basic EPS	358.6	537.9	\$.67	325.2	539.4	\$.60	
Stock options and restricted stock		4.8			6.9		
Convertible preference stock	6.8	36.4		5.4	38.7		
Diluted EPS	\$ 365.4	579.1	\$.63	\$ 330.6	585.0	\$.57	

Nine Months Ended

	September 30, 2003			September 30, 2002			
	-		Per	-		Per	
	Income	Shares	Share	Income	Shares	Share	
Net income	\$ 1,049.2			\$ 947.4			
Preferred dividends	(19.0)			(16.6)			
Basic EPS	1,030.2	537.7	\$ 1.92	930.8	544.5	\$ 1.71	

Edgar Filing: COLGATE PALMOLIVE CO - Form 10-Q

Stock options and restricted stock Convertible preference stock	18.8	5.7 37.0		16.3	7.4 39.4	
Diluted EPS	\$ 1,049.0	580.4	\$ 1.81	\$ 947.1	591.3	\$ 1.60

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in Millions Except Per Share Amounts)

(Unaudited)

6. Stock-Based Compensation

Stock-based compensation plans are accounted for under the provisions of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations. As all grants had an exercise price not less than fair market value on the date of grant, no compensation expense has been recognized for stock option grants. The following presents the effect on net income and earnings per share if the Company had applied the fair value method of Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation:

	September 30,			Nine Months Ended				
				September 30,			30,	
		2003		2002		2003		2002
Net income, as reported	\$	365.4	\$	330.7	\$ 1	,049.2	\$ 9	947.4
Deduct: pro forma stock option compensation expense, net of tax	_	12.2	_	8.8	_	32.0	_	30.2
Pro forma net income	\$	353.2	\$	321.9	\$ 1	,017.2	\$ 9	917.2
			_				_	
Earnings per share:								
Basic as reported	\$.67	\$.60	\$	1.92	\$	1.71
Basic pro forma		.65		.58		1.86		1.65
Diluted as reported		.63		.57		1.81		1.60
Diluted pro forma		.61		.55		1.75		1.55

Pro forma stock option compensation expense above is the estimated fair value of options granted amortized over the vesting period.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in Millions Except Per Share Amounts)

(Unaudited)

Contingencies

In 1995, the Company acquired the Kolynos oral care business from Wyeth (formerly American Home Products) (the Seller), as described in the Company s Form 8-K dated January 10, 1995. On September 8, 1998, the Company s Brazilian subsidiary received notice of an administrative proceeding from the Central Bank of Brazil primarily taking issue with certain foreign exchange filings made with the Central Bank in connection with the financing of this strategic transaction, but in no way challenging or seeking to unwind the acquisition. The Central Bank of Brazil in January 2001 notified the Company of its decision in this administrative proceeding to impose a fine, which, at the current exchange rate, approximates \$90. The Company has appealed the decision to the Brazilian Monetary System Appeals Council (the Council), thereby suspending the fine pending the decision of the Council. If the fine is affirmed, interest and penalties may also be assessed. Further appeals are available within the Brazilian federal courts. Management believes, based on the opinion of its Brazilian legal counsel and other experts, that the filings challenged by the Central Bank fully complied with Brazilian law and that the Company will prevail on appeal. The Company intends to challenge this fine vigorously. In addition, Brazilian prosecutors are reviewing the foregoing transactions as part of an overall examination of all international transfers of Reais through non-resident current accounts during the 1992 to 1998 time frame. The Company understands that this examination involves hundreds and possibly thousands of other individuals and companies. In 2002, the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda., the Brazilian subsidiary of the Seller, and the Company, as represented by its Brazilian subsidiary, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Seller's subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Company's Brazilian subsidiary jointly and severally liable for any tax due from the Seller's subsidiary. Management believes. based on the opinion of its Brazilian legal counsel, that the Company will ultimately prevail in this action. The Company intends to challenge this action vigorously.

In addition, the Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Company s Brazilian subsidiary in connection with the financing of the Kolynos acquisition, imposing a tax assessment that, at the current exchange rate, approximates \$35. At the first level of administrative appeal, the disallowance was confirmed although the amount of the assessment was reduced. The Company and the tax authority have appealed this decision to the First Board of Taxpayers, and further appeals are available within the Brazilian federal courts. Management believes, based on the opinion of its Brazilian legal counsel and other experts, that the disallowance is without merit and that the Company will prevail on appeal. The Company intends to challenge this assessment vigorously.

While it is possible that the Company s cash flows and results of operations in a particular quarter or year could be affected by the one-time impacts of the resolution of such contingencies, it is the opinion of management that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material impact on the Company s financial position, results of operations or ongoing cash flows.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Dollars in Millions Except Per Share Amounts)

(Unaudited)

8. Segment Information

The Company evaluates segment performance based on several factors, including operating profit. The Company uses operating profit as a measure of operating segment performance because it excludes the impact of corporate-driven decisions related to interest expense and income taxes. Net sales and operating profit by business segment and geographic region were as follows:

	Three Mor	Nine Months Ended			
	Septem	ber 30,	September 30,		
	2003	2003 2002		2002	
Net Sales					
Oral, Personal, Household Surface and Fabric Care					
North America	\$ 600.3	\$ 623.5	\$ 1,782.4	\$ 1,753.2	
Latin America	549.0	533.9	1,591.8	1,656.2	
Europe	601.5	532.3	1,710.1	1,466.8	
Asia/Africa	451.0	396.0	1,289.5	1,139.5	
Total Oral, Personal, Household Surface and Fabric Care	2,201.8	2,085.7	6,373.8	6,015.7	
Total Pet Nutrition	322.0	296.0	957.0	858.2	
Total Net Sales	\$ 2,523.8	\$ 2,381.7	\$ 7,330.8	\$ 6,873.9	
			+ 1,000	+ 0,0101	
Operating Profit					
Oral, Personal, Household Surface and Fabric Care					
North America	\$ 131.0	\$ 150.1	\$ 433.7	\$ 429.9	
Latin America	153.1	160.5	453.4	489.7	
Europe	128.0	110.9	369.6	305.7	
Asia/Africa	72.4	58.0	208.0	170.5	
Total Oral, Personal, Household Surface and Fabric Care	484.5	479.5	1,464.7	1,395.8	
Total Pet Nutrition	90.4	78.6	269.4	230.7	
Total Corporate	(39.6)	(44.0)	(130.8)	(133.9)	

Total Operating Profit	\$ 535.3	\$ 514.1	\$ 1,603.3	\$ 1,492.6

9. Subsequent Event

On October 20, 2003, the Company announced its agreement to sell its European laundry detergent brands, marketed in France, Italy and Scandinavia. The sale is subject to approval by regulatory authorities in France. These European laundry detergent brands account for approximately one percent of the Company s annual net sales.

MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in Millions Except Per Share Amounts)

Results of Operations

Worldwide sales reached \$2,523.8 in the third quarter of 2003. Sales increased 6.0% driven by volume gains of 2.5% and a positive foreign exchange impact of 3.5%, as compared to the third quarter of 2002.

Third quarter sales in the Oral, Personal, Household Surface and Fabric Care segment were \$2,201.8, up 5.5% from 2002, on volume growth of 2.0% and a positive foreign exchange impact of 3.5%.

Colgate-North America sales decreased 3.5% in the third quarter of 2003 to \$600.3 as volume declined 3.0% when compared with the third quarter of 2002, which included the successful introduction of Colgate Simply White at-home tooth whitening gel. Despite the volume decline in the region, recently introduced products such as Colgate Total Advanced Fresh, Colgate Total Plus Whitening and Colgate Herbal White toothpastes helped to strengthen its market share in the Oral Care category. In the Personal and Household Surface Care categories, recently introduced products including Palmolive Aromatherapy dishwashing liquid and Mennen Speed Stick 24/7 deodorant achieved volume gains in the region. Operating profit in North America declined 13% to \$131.0 primarily due to decreased volume as compared to the year ago quarter, which included the introduction of Colgate Simply White, and to increased commercial investment.

Colgate-Latin America sales increased 3.0% to \$549.0 as volume grew 1.5% despite challenging macro-economic conditions and currency declines within the region. Strong volume gains in Central America, Colombia, Ecuador and Venezuela were partially offset by volume decreases in the Dominican Republic. Volume was relatively flat in Brazil and Mexico. Recent introductions contributing to growth include Colgate Total Plus Whitening and Colgate Triple Action toothpastes, and Colgate Active Angle and Colgate Extra Clean toothbrushes. Operating profit in Latin America decreased 5% to \$153.1 primarily due to foreign currency declines.

Colgate-Europe sales increased 13.0% to \$601.5 on volume gains of 3.5% and the impact of the stronger euro. Adria, Hungary, Nordic Group, Romania, Russia, Spain, Switzerland, Turkey and the United Kingdom each contributed strong volume gains, offsetting volume declines in Germany and France, which experienced poor economic conditions and negative GDP growth in the period. Successful new products contributing to growth include Colgate Sensitive, Colgate Herbal White and Colgate Whitening toothpastes, and Palmolive Aromatherapy and Palmolive Thermal and Thermal Spa shower gels. Operating profit in Europe grew 15% to \$128.0 driven by volume gains and the positive impact of foreign currencies.

MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in Millions Except Per Share Amounts)

Colgate-Asia/Africa sales increased 14.0% to \$451.0 on volume gains of 9.5% and the positive impact of foreign currencies. Volume growth was achieved in nearly every country in the region led by Australia, China, Hong Kong, India, Malaysia, Morocco, the Philippines, Senegal, South Africa and Taiwan. Successful new products driving Oral Care growth in the region include Colgate Herbal and Colgate Herbal White toothpastes, Colgate Active Angle toothbrush and the continued roll-out of Colgate Simply White at-home tooth whitening gel. Other products driving growth are Palmolive Aromatherapy liquid hand soap and bar soap and Protex Herbal bar soap. Operating profit increased 25% in Asia/Africa to \$72.4 as a result of volume gains, higher gross profit margins and the positive impact of foreign currencies.

Hill s Pet Nutrition sales increased 9.0% to \$322.0 on volume gains of 3.5% and stronger foreign currencies. Hill s increased consumption of Science Diet and Prescription Diet in the U.S. specialty retail channel, where its growth continues to outpace category growth. Hill s Science Diet Nature s Best continues to contribute incremental volume and market share gains, supported with targeted promotional and media spending during the quarter. Internationally, Australia, Japan, Russia, Korea, Switzerland, Taiwan and Thailand each contributed strong volume gains, driven by the continued roll-out of Hill s Science Plan and Science Diet Nature s Best across Europe and Asia. Operating profit at Hill s increased 15% to \$90.4 as a result of increased volume, higher gross profit margins and the positive impact of foreign currencies.

Sales in the Oral, Personal, Household Surface and Fabric Care segment for the nine months ended September 30, 2003 were \$6,373.8, up 6.0% from the comparable period in 2002 as volume rose 4.0%. Within this segment, Colgate-North America sales increased 1.5% on volume growth of 3.5%, Colgate-Latin America sales decreased 4.0% on volume growth of 3.5%, Colgate-Europe sales increased 16.5% on volume growth of 3.0%, and Colgate-Asia/Africa sales increased 13.0% on volume growth of 8.0%.

Sales at Hill s Pet Nutrition for the nine months ended September 30, 2003 increased 11.5% to \$957.0 on volume growth of 5.0% driven by innovative new products, veterinary endorsements and merchandising activities.

Worldwide gross profit margin for the third quarter of 2003 increased to 55.0% from 54.7% in 2002 as the Company continued to benefit from manufacturing cost-reduction initiatives and global sourcing programs, partially offset by the impact of increased commercial investment reflected in net sales. Gross profit margin for the first nine months of 2003 increased to 55.1% from 54.5% in 2002.

Selling, general and administrative expenses as a percent of sales increased to 33.8% in the third quarter of 2003 from 33.1% in 2002, and to 33.2% for the first nine months of 2003 from 32.8% in 2002, reflecting the impact of foreign exchange on expenditures and increased benefit costs, partially offset by continued cost-control initiatives.

Operating profit increased 4% to \$535.3 in the third quarter of 2003, reflecting a level of 21.2% of sales versus 21.6% in the third quarter of 2002. Operating profit increased 7% for the first nine months of 2003 to \$1,603.3, and reached a level of 21.9% of sales versus 21.7% in 2002.

Interest expense, net of interest income, decreased to \$30.4 in the 2003 third quarter as compared with \$38.7 in 2002, and to \$95.7 in the first nine months 2003 from \$110.7 in 2002 reflecting lower interest rates and reduced debt levels.

MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in Millions Except Per Share Amounts)

The effective tax rate for the third quarter of 2003 was 27.6% compared to 30.4% in 2002, reflecting the benefit of tax planning projects in Europe. The effective tax rate for the first nine months of 2003 was 30.4% versus 31.4% in 2002. The tax rate for the first nine months of 2003 reflects the Company s current estimate of its full year effective income tax rate. The Company has continued to benefit from global tax planning strategies which reduce its effective tax rate.

Net income for the third quarter of 2003 increased 10% to \$365.4, or \$0.63 per share on a diluted basis, compared with \$330.7, or \$0.57 per share in the prior year. For the first nine months of 2003, net income increased 11% to \$1,049.2, or \$1.81 per share on a diluted basis compared to \$947.4, or \$1.60 per share in 2002.

For a table summarizing segment sales and operating profit, please refer to Note 8, Segment Information, of the Notes to the Condensed Consolidated Financial Statements.

Liquidity and Capital Resources

Net cash provided by operations increased 6% to \$1,279.7 in the first nine months of 2003, compared with \$1,203.5 in the comparable period of 2002, primarily as a result of improved profitability. Decreased tax payments offset the impact of working capital changes. A portion of the tax payments in the first nine months of 2002 related to a deferral of 2001 taxes into 2002 under a U.S. Government relief program granted to New York City based corporate taxpayers as a result of the events of September 11, 2001. The resulting decrease in tax payments in the first nine months of 2003 was offset by an expected increase in inventory versus low year end levels in line with the timing of new product activities and certain manufacturing relocations. The Company s working capital as a percentage of sales improved to 3.0% of sales as compared to 3.3% of sales in 2002. The Company defines working capital as the difference between current assets (excluding cash and marketable securities reported in other current assets) and current liabilities (excluding short-term debt).

Investing activities during the first nine months include capital expenditures at a level slightly lower than the comparable period of 2002 and proceeds from the sale of various marketable securities and investments including the settlement of certain foreign currency contracts.

The Company has announced its agreement to sell its European laundry detergent brands marketed in France, Italy and Scandinavia. The sale is subject to approval by regulatory authorities in France. The resulting proceeds are expected to fund costs associated with divesting these detergent operations, the continued regionalization of the Company s factories in Europe and a reduction of debt.

Financing activities during the first nine months reflect the 33% increase in quarterly dividends announced in the first quarter, the redemption of all of the outstanding shares of the Company s \$4.25 preferred stock, a planned reduction in share repurchases, and a continued reduction in overall debt levels.

At September 30, 2003, \$579.0 of commercial paper and certain current maturities of notes payable were classified as long-term debt as the Company has the intent and ability to refinance these obligations on a long-term basis under its lines of credit which expire in 2007.

MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in Millions Except Per Share Amounts)

Certain of the Company s financing arrangements require the maintenance of a minimum ratio of operating cash flow to debt. The ESOP notes guaranteed by the Company and certain amounts payable to banks contain cross-default provisions. Non-compliance with these requirements could ultimately result in the acceleration of amounts owed. The Company is in full compliance with all such requirements and believes the likelihood of non-compliance is remote.

For additional information regarding liquidity and capital resources, please refer to the Company s Annual Report on Form 10-K for the year ended December 31, 2002.

This quarterly report on Form 10-Q may contain forward-looking statements. Actual events or results may differ materially from those statements. For information about factors that could cause such differences, please refer to the Company s Annual Report on Form 10-K for the year ended December 31, 2002, including the information set forth under the caption Cautionary Statement on Forward-Looking Statements.

Controls and Procedures

The Company, under the supervision and with the participation of the Company s management, including the Company s Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company s disclosure controls and procedures as of the quarter ended September 30, 2003 (the Evaluation). Based upon the Evaluation, the Company s Chief Executive Officer and Chief Financial Officer concluded that the Company s disclosure controls and procedures are effective in ensuring that material information relating to the Company, including its consolidated subsidiaries, is made known to them by others within those entities, particularly during the period in which this quarterly report was being prepared. There was no change in the Company s internal control over financial reporting that occurred during the Company s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

For information regarding legal matters, please refer to Note 7 to the Condensed Consolidated Financial Statements contained in this quarterly report and Note 13 to the Consolidated Financial Statements included in the Company s Annual Report on Form 10-K for the year ended December 31, 2002.

Item 6. Exhibits and Reports on Form 8-K

(a) I	Exhi	bits:
-------	------	-------

Exhibit 3-A Restated Certificate of Incorporation, as amended.

Exhibit 3-B By-Laws.

Exhibit 12 Ratio of Earnings to Fixed Charges.

Exhibit 31-A Certificate of the Chairman and Chief Executive Officer of

Colgate-Palmolive Company pursuant to Rule 13a-14(a) under

the Securities Exchange Act of 1934.

Exhibit 31-B Certificate of the Chief Financial Officer of Colgate-Palmolive

Company pursuant to Rule 13a-14(a) under the Securities

Exchange Act of 1934.

Exhibit 32 Certificate of the Chairman and Chief Executive Officer and the

Chief Financial Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and

18 U.S.C. Sec. 1350.

(b) Reports on Form 8-K.

On July 22, 2003, the Company furnished a current report on Form 8-K pursuant to Item 12 (Results of Operations and Financial Condition) containing the press release announcing its earnings for the second quarter of 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	(5.1.)	
	(Registrant)	

COLGATE-PALMOLIVE COMPANY

Principal Executive Officer:

November 7, 2003 /s/ Reuben Mark

Reuben Mark Chairman and Chief Executive Officer

Principal Financial Officer:

November 7, 2003 /s/ Stephen C. Patrick

Stephen C. Patrick Chief Financial Officer

Principal Accounting Officer:

November 7, 2003 /s/ Dennis J. Hickey

Dennis J. Hickey Vice President and Corporate Controller

15